<DOC>
	<DOCNO>NCT00552747</DOCNO>
	<brief_summary>Fenofibrate drug act PPAR alpha receptor , increase HDL-cholesterol decrease triglyceride level . The interaction receptor antiatherogenic action regulate expression con key protein participate vascular inflammation , plaque stability thrombosis . Fenofibrate reduce triglycerides increase HDL-C plasma . It also decrease small , dense LDL particle . The use drug result improvement vascular function measure endothelial function . Our hypothesis state fenofibrate improve : endothelial function , improve HDL antioxidant capacity size distribution towards predominance small HDL particle .</brief_summary>
	<brief_title>Effect Fenofibrate Endothelial Function High-density Lipoproteins ( HDL ) Patients With Coronary Heart Disease</brief_title>
	<detailed_description>Patients stable coronary heart disease , LDL-C level goal invite participate randomize , double blind study receive either placebo fenofibrate addition statin therapy .</detailed_description>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Hyperlipidemias</mesh_term>
	<mesh_term>Fenofibrate</mesh_term>
	<criteria>Male patient 1860 year age Stable coronary heart disease ( cardiovascular event 3 month prior enrollment ) Stable lipidmodifying drug therapy ( previous 2 month ) Lowdose statin therapy LDLC goal ( &lt; 100 mg/dl ) Triglyceride level 151500 mg/dl HDLC level &lt; 40 mg/dl Diabetes mellitus Uncontrolled hypertension Systolic blood pressure &gt; 160 mmHg and/or diastolic blood pressure &gt; 100 mmHg Subjects renal ( serum creatinine &gt; 1.5 time upper limit normal ( ULN ) ) , hepatobiliary ( cholelithiasis , biliary cirrhosis , AST and/or ALT &gt; 2x ULN ) active thyroid disease ( TSH &gt; 1.5x ULN &lt; 0.05 uUI/ml ) Hypersensitivity fenofibrate component formula History photoallergic reaction phototoxicity fenofibrate ketoprofen</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>May 2008</verification_date>
	<keyword>fenofibrate</keyword>
	<keyword>coronary heart disease</keyword>
	<keyword>mixed hyperlipidemia</keyword>
</DOC>